Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload

Tetsuro Ago, Yanfei Yang, Peiyong Zhai, Junichi Sadoshima

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Pathological hypertrophy is commonly induced by activation of protein kinases phosphorylating class II histone deacetylases (HDACs) and desuppression of transcription factors, such as nuclear factor of activated T cell (NFAT). We hypothesized that nifedipine, an L-type Ca2+ channel blocker, inhibits Ca2+ calmodulin-dependent kinase II (CaMKII) and NFAT, thereby inhibiting pathological hypertrophy. Mice were subjected to sham operation or transverse aortic constriction (TAC) for 2 weeks with or without nifedipine (10 mg/kg/day). Nifedipine did not significantly alter blood pressure or the pressure gradient across the TAC. Nifedipine significantly suppressed TAC-induced increases in left ventricular (LV) weight/body weight (BW; 5.09∈±∈0.80 vs. 4.16∈±∈0.29 mg/g, TAC without and with nifedipine, n∈=∈6,6, p∈<∈0.05), myocyte cross-sectional area (1,681∈±∈285 vs. 1, 434∈±∈197 arbitrary units, p∈<∈0.05), and expression of fetal-type genes, including atrial natriuretic factor (35. 9∈±∈6.4 vs. 8.6∈±∈3.3 arbitrary units, p∈<∈0.05). TAC-induced increases in lung weight/BW (7.7∈±∈0.9 vs. 5.5∈±∈0.5 mg/g, p∈<∈0.05) and decreases in LV ejection fraction (65.5∈±∈3.1% vs. 75.7∈±∈3.3%, p∈<∈0.05) were attenuated by nifedipine. Nifedipine caused significant inhibition of TAC-induced activation of NFAT-mediated transcription, which was accompanied by suppression of Thr 286 phosphorylation in CaMKII. Nifedipine inhibited activation of CaMKII and NFAT by phenylephrine, accompanied by suppression of Ser 632 phosphorylation and nuclear exit of HDAC4 in cardiac myocytes. These results suggest that a subpressor dose of nifedipine inhibits pathological hypertrophy in the heart by inhibiting activation of CaMKII and NFAT, a signaling mechanism commonly activated in pathological hypertrophy.

Original languageEnglish
Pages (from-to)304-313
Number of pages10
JournalJournal of Cardiovascular Translational Research
Volume3
Issue number4
DOIs
Publication statusPublished - Aug 1 2010
Externally publishedYes

Fingerprint

Cardiomegaly
Left Ventricular Dysfunction
Nifedipine
NFATC Transcription Factors
Pressure
Constriction
Calcium-Calmodulin-Dependent Protein Kinases
Hypertrophy
Phosphorylation
Weights and Measures
Histone Deacetylases
Atrial Natriuretic Factor
Phenylephrine
Cardiac Myocytes
Stroke Volume
Protein Kinases
Muscle Cells
Transcription Factors
Body Weight
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Cite this

Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload. / Ago, Tetsuro; Yang, Yanfei; Zhai, Peiyong; Sadoshima, Junichi.

In: Journal of Cardiovascular Translational Research, Vol. 3, No. 4, 01.08.2010, p. 304-313.

Research output: Contribution to journalArticle

@article{8b9abc2aa775466598efb205a5bb1a01,
title = "Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload",
abstract = "Pathological hypertrophy is commonly induced by activation of protein kinases phosphorylating class II histone deacetylases (HDACs) and desuppression of transcription factors, such as nuclear factor of activated T cell (NFAT). We hypothesized that nifedipine, an L-type Ca2+ channel blocker, inhibits Ca2+ calmodulin-dependent kinase II (CaMKII) and NFAT, thereby inhibiting pathological hypertrophy. Mice were subjected to sham operation or transverse aortic constriction (TAC) for 2 weeks with or without nifedipine (10 mg/kg/day). Nifedipine did not significantly alter blood pressure or the pressure gradient across the TAC. Nifedipine significantly suppressed TAC-induced increases in left ventricular (LV) weight/body weight (BW; 5.09∈±∈0.80 vs. 4.16∈±∈0.29 mg/g, TAC without and with nifedipine, n∈=∈6,6, p∈<∈0.05), myocyte cross-sectional area (1,681∈±∈285 vs. 1, 434∈±∈197 arbitrary units, p∈<∈0.05), and expression of fetal-type genes, including atrial natriuretic factor (35. 9∈±∈6.4 vs. 8.6∈±∈3.3 arbitrary units, p∈<∈0.05). TAC-induced increases in lung weight/BW (7.7∈±∈0.9 vs. 5.5∈±∈0.5 mg/g, p∈<∈0.05) and decreases in LV ejection fraction (65.5∈±∈3.1{\%} vs. 75.7∈±∈3.3{\%}, p∈<∈0.05) were attenuated by nifedipine. Nifedipine caused significant inhibition of TAC-induced activation of NFAT-mediated transcription, which was accompanied by suppression of Thr 286 phosphorylation in CaMKII. Nifedipine inhibited activation of CaMKII and NFAT by phenylephrine, accompanied by suppression of Ser 632 phosphorylation and nuclear exit of HDAC4 in cardiac myocytes. These results suggest that a subpressor dose of nifedipine inhibits pathological hypertrophy in the heart by inhibiting activation of CaMKII and NFAT, a signaling mechanism commonly activated in pathological hypertrophy.",
author = "Tetsuro Ago and Yanfei Yang and Peiyong Zhai and Junichi Sadoshima",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s12265-010-9182-x",
language = "English",
volume = "3",
pages = "304--313",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload

AU - Ago, Tetsuro

AU - Yang, Yanfei

AU - Zhai, Peiyong

AU - Sadoshima, Junichi

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Pathological hypertrophy is commonly induced by activation of protein kinases phosphorylating class II histone deacetylases (HDACs) and desuppression of transcription factors, such as nuclear factor of activated T cell (NFAT). We hypothesized that nifedipine, an L-type Ca2+ channel blocker, inhibits Ca2+ calmodulin-dependent kinase II (CaMKII) and NFAT, thereby inhibiting pathological hypertrophy. Mice were subjected to sham operation or transverse aortic constriction (TAC) for 2 weeks with or without nifedipine (10 mg/kg/day). Nifedipine did not significantly alter blood pressure or the pressure gradient across the TAC. Nifedipine significantly suppressed TAC-induced increases in left ventricular (LV) weight/body weight (BW; 5.09∈±∈0.80 vs. 4.16∈±∈0.29 mg/g, TAC without and with nifedipine, n∈=∈6,6, p∈<∈0.05), myocyte cross-sectional area (1,681∈±∈285 vs. 1, 434∈±∈197 arbitrary units, p∈<∈0.05), and expression of fetal-type genes, including atrial natriuretic factor (35. 9∈±∈6.4 vs. 8.6∈±∈3.3 arbitrary units, p∈<∈0.05). TAC-induced increases in lung weight/BW (7.7∈±∈0.9 vs. 5.5∈±∈0.5 mg/g, p∈<∈0.05) and decreases in LV ejection fraction (65.5∈±∈3.1% vs. 75.7∈±∈3.3%, p∈<∈0.05) were attenuated by nifedipine. Nifedipine caused significant inhibition of TAC-induced activation of NFAT-mediated transcription, which was accompanied by suppression of Thr 286 phosphorylation in CaMKII. Nifedipine inhibited activation of CaMKII and NFAT by phenylephrine, accompanied by suppression of Ser 632 phosphorylation and nuclear exit of HDAC4 in cardiac myocytes. These results suggest that a subpressor dose of nifedipine inhibits pathological hypertrophy in the heart by inhibiting activation of CaMKII and NFAT, a signaling mechanism commonly activated in pathological hypertrophy.

AB - Pathological hypertrophy is commonly induced by activation of protein kinases phosphorylating class II histone deacetylases (HDACs) and desuppression of transcription factors, such as nuclear factor of activated T cell (NFAT). We hypothesized that nifedipine, an L-type Ca2+ channel blocker, inhibits Ca2+ calmodulin-dependent kinase II (CaMKII) and NFAT, thereby inhibiting pathological hypertrophy. Mice were subjected to sham operation or transverse aortic constriction (TAC) for 2 weeks with or without nifedipine (10 mg/kg/day). Nifedipine did not significantly alter blood pressure or the pressure gradient across the TAC. Nifedipine significantly suppressed TAC-induced increases in left ventricular (LV) weight/body weight (BW; 5.09∈±∈0.80 vs. 4.16∈±∈0.29 mg/g, TAC without and with nifedipine, n∈=∈6,6, p∈<∈0.05), myocyte cross-sectional area (1,681∈±∈285 vs. 1, 434∈±∈197 arbitrary units, p∈<∈0.05), and expression of fetal-type genes, including atrial natriuretic factor (35. 9∈±∈6.4 vs. 8.6∈±∈3.3 arbitrary units, p∈<∈0.05). TAC-induced increases in lung weight/BW (7.7∈±∈0.9 vs. 5.5∈±∈0.5 mg/g, p∈<∈0.05) and decreases in LV ejection fraction (65.5∈±∈3.1% vs. 75.7∈±∈3.3%, p∈<∈0.05) were attenuated by nifedipine. Nifedipine caused significant inhibition of TAC-induced activation of NFAT-mediated transcription, which was accompanied by suppression of Thr 286 phosphorylation in CaMKII. Nifedipine inhibited activation of CaMKII and NFAT by phenylephrine, accompanied by suppression of Ser 632 phosphorylation and nuclear exit of HDAC4 in cardiac myocytes. These results suggest that a subpressor dose of nifedipine inhibits pathological hypertrophy in the heart by inhibiting activation of CaMKII and NFAT, a signaling mechanism commonly activated in pathological hypertrophy.

UR - http://www.scopus.com/inward/record.url?scp=77955519404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955519404&partnerID=8YFLogxK

U2 - 10.1007/s12265-010-9182-x

DO - 10.1007/s12265-010-9182-x

M3 - Article

VL - 3

SP - 304

EP - 313

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 4

ER -